A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Shionogi
- Study ID
- NCT07214571
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Respiratory Syncytial Virus Infections
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- S-337395 — DRUGS-337395 will be administered per schedule specified in the arm description.
- Placebo — DRUGPlacebo matched to S-337395 will be administered per schedule specified in the arm description.
Study Details
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
Key Dates
- First listed
- Oct 9, 2025
- Start date
- Dec 11, 2025
- Status verified
- Jul 2026
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
Study Design
- Enrollment
- 192 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: S-337395 High DoseParticipants will receive a high dose of S-337395 twice daily (BID) orally for up to 5 days.
- Experimental: S-337395 Low DoseParticipants will receive a low dose of S-337395 BID orally for up to 5 days.
- Placebo Comparator: PlaceboParticipants will receive matching placebo BID orally for 5 days.
Primary Outcome Measure
Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2 [ Time Frame: Baseline, Day 2 ]
Central Contacts
- Shionogi Clinical Trials Administrator Clinical Support Help Line800-849-9707
Locations (36)
Find similar trials in Los Angeles, CA
By research site
Related Studies
- Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in ChildrenPHASE3 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- A Study of BLB-201 RSV Vaccine in Infants and ChildrenPHASE1/PHASE2 · Recruiting · Blue Lake Biotechnology Inc. · La Mesa, California